Urinary retention and post-void residual urine in men: Separating truth from tradition

被引:113
作者
Kaplan, Steven A. [1 ]
Wein, Alan J. [3 ]
Staskin, David R. [1 ,2 ]
Roehrborn, Claus G. [4 ]
Steers, William D. [5 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Urol, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Dept Obstet Gynecol, New York, NY 10021 USA
[3] Univ Penn Hlth Syst, Div Urol, Philadelphia, PA USA
[4] Univ Texas Dallas, SW Med Ctr, Dept Urol, Dallas, TX USA
[5] Univ Virginia, Sch Med, Dept Urol, Charlottesville, VA 22908 USA
关键词
bladder; urinary retention; male; prostate; muscarinic antagonists;
D O I
10.1016/j.juro.2008.03.027
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The definitions of acute and chronic urinary retention remain empirical and subject to wide interpretation. Standardized criteria have not been established and many questions remain unanswered. Moreover, the definition of significant post-void residual urine is unclear. We reviewed several aspects of urinary retention that require clarification with the objective of stimulating discussion among urologists to establish an accurate and coherent definition of urinary retention and significant post-void residual urine, and clarify risk factors. Materials and Methods: A MEDLINE (R) search for articles written in English and published before April 2007 was done using a list of terms related to urinary retention. Articles not directly relevant to urinary retention or post-void residual urine were excluded. Results: The term urinary retention lacks precise clinical or urodynamic meaning. Use of this term to describe a symptom, a sign, and a condition further complicates the issue. Many factors can contribute to the development of retention, including bladder outlet obstruction, detrusor underactivity, and neurogenic bladder conditions. Community based studies and clinical trials in patients with benign prostatic enlargement and/or lower urinary tract symptoms yield different estimates of the incidence of retention and only provide information on the epidemiology of acute urinary retention. However, age, previous retention episodes, lower urinary tract symptoms, chronic inflammation, serum prostate specific antigen level, prostate size, and urodynamic variables appear to be predictors of acute urinary retention. alpha-Receptor antagonists and 5 alpha-reductase inhibitors may be useful in preventing urinary retention episodes and progressive benign prostatic enlargement. Clinical trials on the short-term use of antimuscarinics have not provided evidence that these agents increase the risk of retention; data on longer term administration are needed. Conclusions: Clinicians are adopting less invasive approaches (eg pharmacology or catheterization) to treating patients who present with the symptoms, sign, and condition of urinary retention. Faced with an abundance of new data on acute urinary retention, urologists need to reach a consensus about the risks of urinary retention; this may promote movement toward patient centered prevention strategies with tailored treatment options.
引用
收藏
页码:47 / 54
页数:8
相关论文
共 55 条
[1]   Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms [J].
Abarbanel, Joseph ;
Marcus, Esther-Lee .
UROLOGY, 2007, 69 (03) :436-440
[2]   URODYNAMIC FINDINGS IN CHRONIC RETENTION OF URINE AND THEIR RELEVANCE TO RESULTS OF SURGERY [J].
ABRAMS, PH ;
DUNN, M ;
GEORGE, N .
BRITISH MEDICAL JOURNAL, 1978, 2 (6147) :1258-1260
[3]   5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery [J].
Boyle, P ;
Roehrborn, C ;
Harkaway, R ;
Logie, J ;
de la Rosette, J ;
Emberton, M .
EUROPEAN UROLOGY, 2004, 45 (05) :620-627
[4]   Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England [J].
Cathcart, Paul ;
van der Meulen, Jan ;
Armitage, Jim ;
Emberton, Mark .
JOURNAL OF UROLOGY, 2006, 176 (01) :200-204
[5]  
Cespedes R D, 2001, Tech Urol, V7, P118
[6]   Urodynamic pattern chances in multiple sclerosis [J].
Ciancio, SJ ;
Mutchnik, SE ;
Rivera, VM ;
Boone, TB .
UROLOGY, 2001, 57 (02) :239-245
[7]   Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo [J].
Crawford, ED ;
Wilson, SS ;
McConnell, JD ;
Slawin, KM ;
Lieber, MC ;
Smith, JA ;
Meehan, AG ;
Bautista, OM ;
Noble, WR ;
Kusek, JW ;
Nyberg, LM ;
Roehrborn, CG .
JOURNAL OF UROLOGY, 2006, 175 (04) :1422-1426
[8]   Transvaginal urethrolysis for urethral obstruction after anti-incontinence surgery [J].
Cross, CA ;
Cespedes, RD ;
English, SF ;
McGuire, EJ .
JOURNAL OF UROLOGY, 1998, 159 (04) :1199-1201
[9]   Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia [J].
Debruyne, F ;
Barkin, J ;
van Erps, P ;
Reis, M ;
Tammela, TLJ ;
Roehrborn, C .
EUROPEAN UROLOGY, 2004, 46 (04) :488-495
[10]   Drug-induced bladder and urinary disorders - Incidence, prevention and management [J].
Drake, MJ ;
Nixon, PM ;
Crew, JP .
DRUG SAFETY, 1998, 19 (01) :45-55